Palvella Therapeutics, Inc. Operating Cash Flow
Palvella Therapeutics, Inc. (PVLA) reported Operating Cash Flow of -$23.71 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-04
- Palvella Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$12.85M.
- Palvella Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$10.86M.
- Palvella Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$4.93M.
- Palvella Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$7.88M.
- Palvella Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$25.01M.
- Palvella Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$10.84M.
- Palvella Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$13.70M.
- Palvella Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$59.93M.
| Period end | Net Cash Provided by (Used in) Operating Activities 1 month | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 7 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 10 month | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed | Net Cash Provided by (Used in) Operating Activities 13 month | Net Cash Provided by (Used in) Operating Activities 16 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$12.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$23.71M 10-Q · filed 2026-08-04 | -$28.64M derived: sum of 3 quarters · filed 2026-08-04 | -$36.51M derived: sum of 4 quarters · filed 2026-08-04 | |||||||||
| 2026-03-31 | -$10.86M 10-Q · filed 2026-05-07 | -$15.79M derived: sum of 2 quarters · filed 2026-05-07 | -$23.67M derived: sum of 3 quarters · filed 2026-05-07 | -$29.10M derived: sum of 4 quarters · filed 2026-08-04 | |||||||||
| 2025-12-31 | -$4.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$12.80M derived: sum of 2 quarters · filed 2026-03-31 | -$18.24M derived: sum of 3 quarters · filed 2026-08-04 | -$25.01M 10-K · filed 2026-03-31 | |||||||||
| 2025-09-30 | -$7.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$13.31M derived: sum of 2 quarters · filed 2026-08-04 | -$20.08M 10-Q · filed 2025-11-12 | -$25.47M derived: sum of 4 quarters · filed 2026-08-04 | |||||||||
| 2025-06-30 | -$5.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$12.20M 10-Q · filed 2026-08-04 | -$17.59M derived: sum of 3 quarters · filed 2026-08-04 | -$20.34M derived: sum of 4 quarters · filed 2026-08-04 | |||||||||
| 2025-03-31 | -$6.77M 10-Q · filed 2026-05-07 | -$12.16M derived: sum of 2 quarters · filed 2026-05-07 | -$14.90M derived: sum of 3 quarters · filed 2026-05-07 | -$16.51M derived: sum of 4 quarters · filed 2026-05-07 | |||||||||
| 2024-12-31 | -$5.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$8.13M derived: sum of 2 quarters · filed 2026-03-31 | -$9.74M derived: sum of 3 quarters · filed 2026-03-31 | -$10.84M 10-K · filed 2026-03-31 | |||||||||
| 2024-09-30 | -$2.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$4.34M derived: sum of 2 quarters · filed 2025-11-12 | -$5.45M 10-Q · filed 2025-11-12 | -$8.33M 10-Q · filed 2024-11-13 | $15.00M derived: sum of 4 quarters · filed 2025-11-12 | ||||||||
| 2024-06-30 | -$1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$2.71M 10-Q · filed 2025-08-14 | -$8.48M 10-Q · filed 2024-08-14 | $17.74M derived: sum of 3 quarters · filed 2025-08-14 | $8.02M derived: sum of 4 quarters · filed 2025-08-14 | ||||||||
| 2024-03-31 | -$1.10M 10-Q · filed 2025-05-15 | -$7.00M 10-Q · filed 2024-05-15 | $19.34M derived: sum of 2 quarters · filed 2025-05-15 | $9.62M derived: sum of 3 quarters · filed 2025-05-15 | -$3.81M derived: sum of 4 quarters · filed 2025-05-15 | ||||||||
| 2023-12-31 | $20.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $10.72M derived: sum of 2 quarters · filed 2025-03-31 | -$2.71M derived: sum of 3 quarters · filed 2025-03-31 | -$13.70M 10-K · filed 2025-03-31 | -$53.82M 10-K · filed 2024-03-29 | ||||||||
| 2023-09-30 | -$9.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$23.15M derived: sum of 2 quarters · filed 2024-11-13 | -$34.15M 10-Q · filed 2024-11-13 | -$47.08M derived: sum of 4 quarters · filed 2024-11-13 | |||||||||
| 2023-06-30 | -$13.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$24.43M 10-Q · filed 2024-08-14 | -$37.36M derived: sum of 3 quarters · filed 2024-08-14 | -$46.14M derived: sum of 4 quarters · filed 2024-08-14 | |||||||||
| 2023-03-31 | -$11.00M 10-Q · filed 2024-05-15 | -$23.93M derived: sum of 2 quarters · filed 2024-05-15 | -$32.71M derived: sum of 3 quarters · filed 2024-05-15 | -$48.28M derived: sum of 4 quarters · filed 2024-05-15 | |||||||||
| 2022-12-31 | -$12.93M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$21.71M derived: sum of 2 quarters · filed 2024-03-29 | -$37.29M derived: sum of 3 quarters · filed 2024-03-29 | -$59.93M 10-K · filed 2024-03-29 | |||||||||
| 2022-09-30 | -$8.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$24.36M derived: sum of 2 quarters · filed 2023-11-14 | -$47.00M 10-Q · filed 2023-11-14 | -$57.94M derived: sum of 4 quarters · filed 2023-11-14 | |||||||||
| 2022-06-30 | -$15.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$38.22M 10-Q · filed 2023-08-10 | -$49.16M derived: sum of 3 quarters · filed 2023-08-10 | -$63.65M derived: sum of 4 quarters · filed 2023-08-10 | |||||||||
| 2022-03-31 | -$22.64M 10-Q · filed 2023-05-11 | -$33.59M derived: sum of 2 quarters · filed 2023-05-11 | -$48.07M derived: sum of 3 quarters · filed 2023-05-11 | -$18.16M derived: sum of 4 quarters · filed 2023-05-11 | |||||||||
| 2021-12-31 | -$10.94M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$25.43M derived: sum of 2 quarters · filed 2023-03-31 | $4.48M derived: sum of 3 quarters · filed 2023-03-31 | -$7.66M 10-K · filed 2023-03-31 | |||||||||
| 2021-09-30 | -$14.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $15.42M derived: sum of 2 quarters · filed 2022-11-04 | $3.28M 10-Q · filed 2022-11-04 | -$10.13M derived: sum of 4 quarters · filed 2022-11-04 | |||||||||
| 2021-06-30 | $29.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $17.77M 10-Q · filed 2022-08-04 | $4.35M derived: sum of 3 quarters · filed 2022-08-04 | -$3.22M derived: sum of 4 quarters · filed 2022-08-04 | |||||||||
| 2021-03-31 | -$12.14M 10-Q · filed 2022-05-11 | -$25.55M derived: sum of 2 quarters · filed 2022-05-11 | -$33.13M derived: sum of 3 quarters · filed 2022-05-11 | -$42.90M derived: sum of 4 quarters · filed 2022-05-11 | |||||||||
| 2020-12-31 | -$13.42M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | -$20.99M derived: sum of 2 quarters · filed 2022-03-02 | -$30.77M derived: sum of 3 quarters · filed 2022-03-02 | -$45.90M 10-K · filed 2022-03-02 | |||||||||
| 2020-09-30 | -$7.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | -$17.35M derived: sum of 2 quarters · filed 2021-11-02 | -$32.48M 10-Q · filed 2021-11-02 | -$46.45M derived: sum of 4 quarters · filed 2021-11-02 | |||||||||
| 2020-06-30 | -$9.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$24.91M 10-Q · filed 2021-08-05 | -$38.88M derived: sum of 3 quarters · filed 2021-08-05 | -$51.53M derived: sum of 4 quarters · filed 2021-08-05 | |||||||||
| 2020-03-31 | -$15.13M 10-Q · filed 2021-05-17 | -$29.11M derived: sum of 2 quarters · filed 2021-05-17 | -$41.76M derived: sum of 3 quarters · filed 2021-05-17 | -$52.49M derived: sum of 4 quarters · filed 2021-05-17 | |||||||||
| 2019-12-31 | -$13.97M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | -$26.63M derived: sum of 2 quarters · filed 2021-03-31 | -$37.36M derived: sum of 3 quarters · filed 2021-03-31 | -$52.47M 10-K · filed 2021-03-31 | |||||||||
| 2019-09-30 | -$12.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$23.39M derived: sum of 2 quarters · filed 2020-11-04 | -$38.49M 10-Q · filed 2020-11-04 | -$47.55M derived: sum of 4 quarters · filed 2020-11-04 | |||||||||
| 2019-06-30 | -$10.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$25.84M 10-Q · filed 2020-08-10 | -$34.90M derived: sum of 3 quarters · filed 2020-08-10 | -$49.26M derived: sum of 4 quarters · filed 2020-08-10 | |||||||||
| 2019-03-31 | -$15.11M 10-Q · filed 2020-05-11 | -$24.17M derived: sum of 2 quarters · filed 2020-05-11 | -$38.52M derived: sum of 3 quarters · filed 2020-05-11 | -$47.51M derived: sum of 4 quarters · filed 2020-05-11 | |||||||||
| 2018-12-31 | -$9.06M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | -$23.42M derived: sum of 2 quarters · filed 2020-03-13 | -$32.41M derived: sum of 3 quarters · filed 2020-03-13 | -$1.07M 10-K · filed 2020-03-13 | |||||||||
| 2018-09-30 | -$14.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$23.35M derived: sum of 2 quarters · filed 2019-11-12 | $7.99M 10-Q · filed 2019-11-12 | ||||||||||
| 2018-06-30 | -$8.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $22.35M 10-Q · filed 2019-08-09 | |||||||||||
| 2018-03-31 | $31.34M 10-Q · filed 2019-05-10 | ||||||||||||
| 2017-12-31 | $49.75M 10-K · filed 2019-03-18 | ||||||||||||
| 2014-09-30 | -$13.92K 10-Q · filed 2014-11-13 | -$21.98K derived: sum of 2 quarters · filed 2014-11-13 | -$22.27K derived: sum of 3 quarters · filed 2014-11-13 | -$23.22K derived: sum of 4 quarters · filed 2014-11-13 | -$29.25K 10-Q · filed 2014-11-13 | ||||||||
| 2014-06-30 | -$8.06K derived: 10-K 12 month − 10-Q 9 month · filed 2014-09-12 | -$8.35K derived: sum of 2 quarters · filed 2014-09-12 | -$9.30K derived: sum of 3 quarters · filed 2014-09-12 | -$15.06K 10-K · filed 2014-09-12 | -$15.34K 10-K · filed 2014-09-12 | ||||||||
| 2014-03-31 | -$294.00 10-Q · filed 2014-06-02 | -$1.24K derived: sum of 2 quarters · filed 2014-06-02 | -$7.00K 10-Q · filed 2014-06-02 | -$7.00K 10-Q · filed 2014-06-02 | |||||||||
| 2013-12-31 | -$948.00 10-Q · filed 2014-05-14 | -$6.71K 10-Q · filed 2014-05-14 | -$6.71K 10-Q · filed 2014-05-14 | ||||||||||
| 2013-09-30 | -$4.51K 10-Q · filed 2014-12-12 | ||||||||||||
| 2013-06-30 | -$274.00 10-K · filed 2014-09-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |